Active ingredientBaxdrostatCat. No. P-B013-001CAS 1428652-17-8Family · Pharmaceutical analytical standards
Baxdrostat
An aldosterone synthase inhibitor, blocking the enzyme that makes aldosterone, approved in the United States in 2026 for high blood pressure alongside other antihypertensives, after a phase 3 trial showed significant drops in blood pressure. This family brings together the active ingredient, labelled standards and other impurities.
Did you know?Instead of blocking the receptor that aldosterone acts on, as the traditional drugs of this kind do, it directly curbs aldosterone production: in 2026 it became the first aldosterone synthase inhibitor approved in the US for high blood pressure.
Go to the active ingredient →Active ingredientBaxdrostatCat. No. P-B013-001CAS 1428652-17-8
Isotopically labelledBaxdrostat-d3Cat. No. P-B013-002
Impurity(S)-BaxdrostatCat. No. P-B013-003CAS 1428652-16-7
ImpurityBaxdrostat N-OxideCat. No. P-B013-004
ImpurityN-Desmethyl BaxdrostatCat. No. P-B013-005
Impurityrac-BaxdrostatCat. No. P-B013-006CAS 1428652-15-6No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.